254 related articles for article (PubMed ID: 23221323)
1. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database.
Schneeberger D; Tyndall A; Kay J; Søndergaard KH; Carreira PE; Morgiel E; Deuschle K; Derk CT; Widuchowska M; Walker UA
Rheumatology (Oxford); 2013 Mar; 52(3):560-7. PubMed ID: 23221323
[TBL] [Abstract][Full Text] [Related]
2. Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis.
Minier T; Guiducci S; Bellando-Randone S; Bruni C; Lepri G; Czirják L; Distler O; Walker UA; Fransen J; Allanore Y; Denton C; Cutolo M; Tyndall A; Müller-Ladner U; Matucci-Cerinic M; ;
Ann Rheum Dis; 2014 Dec; 73(12):2087-93. PubMed ID: 23940211
[TBL] [Abstract][Full Text] [Related]
3. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database.
Walker UA; Tyndall A; Czirják L; Denton C; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Bocelli-Tyndall C; Matucci-Cerinic M
Ann Rheum Dis; 2007 Jun; 66(6):754-63. PubMed ID: 17234652
[TBL] [Abstract][Full Text] [Related]
4. Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database.
Carreira PE; Carmona L; Joven BE; Loza E; Andreu JL; Riemekasten G; Vettori S; Balbir-Gurman A; Airò P; Walker UA; Damjanov N; Matucci-Cerinic M; Ananieva LP; Rednic S; Czirják L; Distler O; Farge D; Hesselstrand R; Corrado A; Caramaschi P; Tikly M; Allanore Y;
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):68-75. PubMed ID: 30277860
[TBL] [Abstract][Full Text] [Related]
5. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.
Meier FM; Frommer KW; Dinser R; Walker UA; Czirjak L; Denton CP; Allanore Y; Distler O; Riemekasten G; Valentini G; Müller-Ladner U;
Ann Rheum Dis; 2012 Aug; 71(8):1355-60. PubMed ID: 22615460
[TBL] [Abstract][Full Text] [Related]
6. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
7. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
[TBL] [Abstract][Full Text] [Related]
8. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis.
Koenig M; Joyal F; Fritzler MJ; Roussin A; Abrahamowicz M; Boire G; Goulet JR; Rich E; Grodzicky T; Raymond Y; Senécal JL
Arthritis Rheum; 2008 Dec; 58(12):3902-12. PubMed ID: 19035499
[TBL] [Abstract][Full Text] [Related]
10. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS).
Bellando-Randone S; Del Galdo F; Lepri G; Minier T; Huscher D; Furst DE; Allanore Y; Distler O; Czirják L; Bruni C; Guiducci S; Avouac J; Cutolo M; Smith V; Matucci-Cerinic M;
Lancet Rheumatol; 2021 Dec; 3(12):e834-e843. PubMed ID: 38287630
[TBL] [Abstract][Full Text] [Related]
11. Clinical and serological heterogeneity in patients with anticentromere antibodies.
Miyawaki S; Asanuma H; Nishiyama S; Yoshinaga Y
J Rheumatol; 2005 Aug; 32(8):1488-94. PubMed ID: 16078324
[TBL] [Abstract][Full Text] [Related]
12. Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining.
Ceribelli A; Krzyszczak ME; Li Y; Ross SJ; Chan JY; Chan EK; Burlingame RW; Webb TT; Bubb MR; Sobel ES; Reeves WH; Satoh M
Arthritis Res Ther; 2011 Jul; 13(4):R119. PubMed ID: 21781293
[TBL] [Abstract][Full Text] [Related]
13. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
14. Time to diagnosis in systemic sclerosis: is sex a factor?
Hudson M; Thombs B; Baron M;
Arthritis Rheum; 2009 Feb; 61(2):274-8. PubMed ID: 19177534
[TBL] [Abstract][Full Text] [Related]
15. Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database.
Walker UA; Tyndall A; Czirják L; Denton CP; Farge-Bancel D; Kowal-Bielecka O; Müller-Ladner U; Matucci-Cerinic M;
Ann Rheum Dis; 2009 Jun; 68(6):856-62. PubMed ID: 18625615
[TBL] [Abstract][Full Text] [Related]
16. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
Tyndall AJ; Bannert B; Vonk M; Airò P; Cozzi F; Carreira PE; Bancel DF; Allanore Y; Müller-Ladner U; Distler O; Iannone F; Pellerito R; Pileckyte M; Miniati I; Ananieva L; Gurman AB; Damjanov N; Mueller A; Valentini G; Riemekasten G; Tikly M; Hummers L; Henriques MJ; Caramaschi P; Scheja A; Rozman B; Ton E; Kumánovics G; Coleiro B; Feierl E; Szucs G; Von Mühlen CA; Riccieri V; Novak S; Chizzolini C; Kotulska A; Denton C; Coelho PC; Kötter I; Simsek I; de la Pena Lefebvre PG; Hachulla E; Seibold JR; Rednic S; Stork J; Morovic-Vergles J; Walker UA
Ann Rheum Dis; 2010 Oct; 69(10):1809-15. PubMed ID: 20551155
[TBL] [Abstract][Full Text] [Related]
17. Application of the 2013 ACR/EULAR classification criteria for systemic sclerosis to patients with Raynaud's phenomenon.
Park JS; Park MC; Song JJ; Park YB; Lee SK; Lee SW
Arthritis Res Ther; 2015 Mar; 17(1):77. PubMed ID: 25889905
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis.
Hong P; Pope JE; Ouimet JM; Rullan E; Seibold JR
J Rheumatol; 2004 Mar; 31(3):508-13. PubMed ID: 14994396
[TBL] [Abstract][Full Text] [Related]
19. Juvenile systemic sclerosis: a follow-up study of eight patients.
Szamosi S; Maródi L; Czirják L; Ellenes Z; Szücs G
Ann N Y Acad Sci; 2005 Jun; 1051():229-34. PubMed ID: 16126963
[TBL] [Abstract][Full Text] [Related]
20. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
